Clinical Trials Browser

Lung Neoplasms × cobimetinib × Clear all

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03600701 2025-10-07

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Phase 2 Active not recruiting

51 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03989115 2023-06-26

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Phase 1/2 Completed

113 enrolled 22 charts

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Noonan Syndrome, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

Clinical Trials

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC